resume 2025
Category: 2025
Transgene Announces the Success of Its Capital Increase
Results 2025
Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Suspension 2025
Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery
P. Erbs, et al. Cancers 2025 Abstract available on the MDPI website – Download the article
TG4050 at 2025 SITC: New Ph.I immunological data
link to webcast
VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production
B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster
Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
C. Le Tourneau, et al. SITC 2025 Abstract available on JITC website – Download the abstract – Download the Poster
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
ESMO AI 2026
Contribution of yeast to synthetic virology
C. Rey, et al. Virologie 2025 Read the article on the JLE website – Download the article
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
ESMO Poster